Real-World study confirms Tildrakizumab's effectiveness for psoriasis
NCT ID NCT04203693
First seen Mar 04, 2026 · Last updated Apr 30, 2026 · Updated 7 times
Summary
This observational study followed 331 adults with moderate to severe plaque psoriasis who were treated with tildrakizumab (Ilumetri®) in routine clinical practice. Researchers measured skin clearance (using PASI scores) and quality of life over up to 2 years. The goal was to see how well the drug works outside of clinical trials and how doctors prescribe it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site 1
Nice, France
-
Investigational Site 1
Augsburg, Germany
-
Investigational Site 1
Arezzo, Italy
-
Investigational Site 10
Cologne, Germany
-
Investigational Site 10
Roma, Italy
-
Investigational Site 11
Lübeck, Germany
-
Investigational Site 11
Roma, Italy
-
Investigational Site 12
München, Germany
-
Investigational Site 12
Rozzano, Italy
-
Investigational Site 13
Merzig, Germany
-
Investigational Site 14
Oberursel, Germany
-
Investigational Site 15
Quedlinburg, Germany
-
Investigational Site 2
Berlin, Germany
-
Investigational Site 2
Brescia, Italy
-
Investigational Site 3
Bochum, Germany
-
Investigational Site 3
Catania, Italy
-
Investigational Site 4
Erlangen, Germany
-
Investigational Site 4
Florence, Italy
-
Investigational Site 5
Greifswald, Germany
-
Investigational Site 5
Genova, Italy
-
Investigational Site 6
Hamburg, Germany
-
Investigational Site 6
Lecce, Italy
-
Investigational Site 7
Halle, Germany
-
Investigational Site 7
Modena, Italy
-
Investigational Site 8
Kiel, Germany
-
Investigational Site 8
Roma, Italy
-
Investigational Site 9
Kiel, Germany
-
Investigational Site 9
Roma, Italy
-
Investigational site 1
Breda, Netherlands
-
Investigator Site 1
Baden, Austria
-
Investigator Site 1
Brussels, Belgium
-
Investigator Site 2
Vienna, Austria
-
Investigator Site 2
Charleroi, Belgium
-
Investigator Site 2
Poitiers, France
-
Investigator Site 3
Genk, Belgium
-
Investigator Site 4
Ghent, Belgium
-
Investigator Site 5
Herstal, Belgium
-
Investigator Site 6
Jette, Belgium
-
Investigator Site 7
Lede, Belgium
-
Investigator Site 8
Leuven, Belgium
-
Investigator Site 9
Mons, Belgium
Conditions
Explore the condition pages connected to this study.